Why Cree, Pacific Biosciences of California, and Datalink Plunged Today

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Concerns about the sustainability of the global economic recovery helped push the stock market down from record levels today, as the wildcard of the government shutdown will likely keep investors on edge for months until economic data become available. Amid modest stock market losses of around half a percent, Cree , Pacific Biosciences of California , and Datalink all fell much more dramatically today. Let's take a closer look to find out why these companies were market victims today.

Cree lost 17% of its share price today after the LED-lighting specialist disappointed investors with its earnings report. Even though a 24% rise in sales led to gains in net income of 89%, investors were hoping for a slightly faster pace of revenue growth from Cree. Even worse, Cree's guidance for the December quarter fell well below expectations. With the stock still trading at more than 80 times trailing earnings, Cree simply has no margin for error with high-growth investors who are counting on the strongest results possible.


Earnings were also the culprit for Pacific Biosciences of California, which dropped 19% after its third-quarter report. A drop in sales of its key DNA sequencing units hurt its results somewhat, although the company's loss was only marginally worse than investors had expected. The big question for Pacific Biosciences looking forward is whether it can turn its sophisticated genetic equipment into steady streams of cash flow, and until it does so, skeptical investors will likely keep scorning the company.

Datalink was the biggest decliner of the three, falling 24%. Earnings once again were to blame, as the company proved unable to convert rising revenue into greater profits. In particular, earnings-per-share figures that missed investors' projections by almost half led to a loss of confidence in the data-center infrastructure provider. With Big Data remaining a high-growth opportunity, Datalink isn't down for the count, but it will need to step up its game to compete with the rising number of players seeking their fortunate from data storage and analysis.

Is Datalink the best data play?
Rising amounts of data storage make for a huge investment opportunity, and The Motley Fool wants to help you cash in on it. To make sense of the trend, we've compiled a new report called "The Only Stock You Need to Profit From the NEW Technology Revolution." The report highlights a company that has gained 300% since first recommended by Fool analysts but still has plenty of room left to run. To get instant access to the name of this company transforming the IT industry, click here -- it's free.

The article Why Cree, Pacific Biosciences of California, and Datalink Plunged Today originally appeared on Fool.com.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Add a Comment

*0 / 3000 Character Maximum